Ann-Kathrin Eisfeld | Molecular Profiles | Best Researcher Award Published on 20/09/202520/09/2025 by Cell Biologist Prof. Dr. Ann-Kathrin Eisfeld | Molecular Profiles | Best Researcher Award The Ohio State University | United States Dr. Ann-Kathrin Eisfeld is an internationally recognized physician-scientist and Associate Professor with Tenure in the Division of Hematology at The Ohio State University, where she also serves as Director of the Clara D. Bloomfield Center for Leukemia Outcomes Research. Her research focuses on the molecular and genetic underpinnings of acute myeloid leukemia (AML), with a particular emphasis on translational applications that improve patient outcomes. Dr. Eisfeld has published extensively in high-impact journals such as Nature, Leukemia, Blood, and Cell Stem Cell, contributing significantly to our understanding of leukemia biology, clonal evolution, and treatment resistance. she has authored over 100 peer-reviewed scientific publications, with an h-index of 38, more than 6,500 citations, and has led or co-led multiple collaborative studies within national consortia such as the Alliance for Clinical Trials in Oncology. Her work has identified critical biomarkers and therapeutic targets in AML, including insights into TP53 mutations, FLT3 alterations, and resistance mechanisms to venetoclax. Recognized for her integration of clinical insight with cutting-edge genomics, Dr. Eisfeld is a leading voice in precision oncology and leukemia research, shaping the future of individualized treatment strategies through both clinical innovation and scientific discovery. Profile: Scopus Featured Publications: “Highly elevated serum hepcidin in patients with acute myeloid leukemia prior to and after allogeneic hematopoietic cell transplantation: Does this protect from excessive parenchymal iron loading?” “Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia” “miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia” “Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia” “Kinetics of iron removal by phlebotomy in patients with iron overload after allogeneic hematopoietic cell transplantation” “inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations” “Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients” “In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline” “A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia”
Dr. Ann-Kathrin Eisfeld is an internationally recognized physician-scientist and Associate Professor with Tenure in the Division of Hematology at The Ohio State University, where she also serves as Director of the Clara D. Bloomfield Center for Leukemia Outcomes Research. Her research focuses on the molecular and genetic underpinnings of acute myeloid leukemia (AML), with a particular emphasis on translational applications that improve patient outcomes. Dr. Eisfeld has published extensively in high-impact journals such as Nature, Leukemia, Blood, and Cell Stem Cell, contributing significantly to our understanding of leukemia biology, clonal evolution, and treatment resistance. she has authored over 100 peer-reviewed scientific publications, with an h-index of 38, more than 6,500 citations, and has led or co-led multiple collaborative studies within national consortia such as the Alliance for Clinical Trials in Oncology. Her work has identified critical biomarkers and therapeutic targets in AML, including insights into TP53 mutations, FLT3 alterations, and resistance mechanisms to venetoclax. Recognized for her integration of clinical insight with cutting-edge genomics, Dr. Eisfeld is a leading voice in precision oncology and leukemia research, shaping the future of individualized treatment strategies through both clinical innovation and scientific discovery. Profile: Scopus Featured Publications: “Highly elevated serum hepcidin in patients with acute myeloid leukemia prior to and after allogeneic hematopoietic cell transplantation: Does this protect from excessive parenchymal iron loading?” “Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia” “miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia” “Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia” “Kinetics of iron removal by phlebotomy in patients with iron overload after allogeneic hematopoietic cell transplantation” “inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations” “Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients” “In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline” “A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia”
Ali Alahmari | Stem Cell Transplantation | Best Researcher Award Published on 18/09/202518/09/2025 by Cell Biologist Dr. Ali Alahmari | Stem Cell Transplantation | Best Researcher Award Kfshrc | Saudi Arabia Dr. Ali Alahmari is a distinguished consultant in Acute Leukemia, Hematology, Hematopoietic Stem Cell Transplantation (HSCT), and Cellular Therapy at King Faisal Specialist Hospital & Research Centre. He earned his MBBS degree from King Saud University and completed his internship at King Khalid University Hospital. He has held a key consultant position, contributing extensively to the advancement of cellular therapy and bone marrow transplantation in Saudi Arabia. Dr. Alahmari has made significant academic contributions to the field, particularly in hemato-hepatology and sickle cell disease. His research has focused on novel transplant approaches, including haploidentical stem cell transplantation after liver transplantation and donor impact in severe aplastic anemia. He has co-authored over 22 scientific documents, with his work accumulating more than 629 citations and earning an h-index of 12, reflecting the depth and influence of his research. His notable publications include titles such as “Donor impact on allogeneic transplant outcomes with PTCy for severe aplastic anemia“ and “Haplo-stem cell transplant post liver transplantation to cure sickle cell disease with related liver dysfunction.” Dr. Alahmari’s ongoing efforts continue to shape clinical best practices and research frameworks for hematologic disorders and transplantation medicine in the region. Profile: Scopus Featured Publications: “Author Correction: Haplo-stem cell transplant post liver transplantation to cure sickle cell disease with related liver dysfunction: a case series” “Donor impact on allogeneic transplant outcomes with PTCy for severe aplastic anemia: a study of the SAAWP EBMT” “Emerging need for a hepato-hematology program for patients with sickle cell disease in Saudi Arabia” “Haplo-stem cell transplant post liver transplantation to cure sickle cell disease with related liver dysfunction: a case series” “Hematopoietic Stem Cell Transplantation in Sickle Cell Disease” “Setting up a Chimeric Antigen Receptor T Cell Therapy Program: A Framework for Delivery from the Worldwide Network for Blood & Marrow Transplantation” “Outcomes of human leukocyte antigen matched sibling transplant from consanguineous versus non-consanguineous parents, a single center experience”
Dr. Ali Alahmari is a distinguished consultant in Acute Leukemia, Hematology, Hematopoietic Stem Cell Transplantation (HSCT), and Cellular Therapy at King Faisal Specialist Hospital & Research Centre. He earned his MBBS degree from King Saud University and completed his internship at King Khalid University Hospital. He has held a key consultant position, contributing extensively to the advancement of cellular therapy and bone marrow transplantation in Saudi Arabia. Dr. Alahmari has made significant academic contributions to the field, particularly in hemato-hepatology and sickle cell disease. His research has focused on novel transplant approaches, including haploidentical stem cell transplantation after liver transplantation and donor impact in severe aplastic anemia. He has co-authored over 22 scientific documents, with his work accumulating more than 629 citations and earning an h-index of 12, reflecting the depth and influence of his research. His notable publications include titles such as “Donor impact on allogeneic transplant outcomes with PTCy for severe aplastic anemia“ and “Haplo-stem cell transplant post liver transplantation to cure sickle cell disease with related liver dysfunction.” Dr. Alahmari’s ongoing efforts continue to shape clinical best practices and research frameworks for hematologic disorders and transplantation medicine in the region. Profile: Scopus Featured Publications: “Author Correction: Haplo-stem cell transplant post liver transplantation to cure sickle cell disease with related liver dysfunction: a case series” “Donor impact on allogeneic transplant outcomes with PTCy for severe aplastic anemia: a study of the SAAWP EBMT” “Emerging need for a hepato-hematology program for patients with sickle cell disease in Saudi Arabia” “Haplo-stem cell transplant post liver transplantation to cure sickle cell disease with related liver dysfunction: a case series” “Hematopoietic Stem Cell Transplantation in Sickle Cell Disease” “Setting up a Chimeric Antigen Receptor T Cell Therapy Program: A Framework for Delivery from the Worldwide Network for Blood & Marrow Transplantation” “Outcomes of human leukocyte antigen matched sibling transplant from consanguineous versus non-consanguineous parents, a single center experience”
“Author Correction: Haplo-stem cell transplant post liver transplantation to cure sickle cell disease with related liver dysfunction: a case series” “Donor impact on allogeneic transplant outcomes with PTCy for severe aplastic anemia: a study of the SAAWP EBMT” “Emerging need for a hepato-hematology program for patients with sickle cell disease in Saudi Arabia” “Haplo-stem cell transplant post liver transplantation to cure sickle cell disease with related liver dysfunction: a case series” “Hematopoietic Stem Cell Transplantation in Sickle Cell Disease” “Setting up a Chimeric Antigen Receptor T Cell Therapy Program: A Framework for Delivery from the Worldwide Network for Blood & Marrow Transplantation” “Outcomes of human leukocyte antigen matched sibling transplant from consanguineous versus non-consanguineous parents, a single center experience”